A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

비만과 제2형 당뇨병을 함께 조절할 수 있는 새로운 치료 후보가 등장했다. 암젠(Amgen)이 개발 중인 마리타이드(MariTide, 성분명: Maridebart Cafraglutide )는 월 1회 투여 방식의 장기 지속형 ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

(사진=연합뉴스) [알파경제=김민영 기자] 글로벌 바이오 제약사인 암젠(AMGN.N)이 최근 비만 시장 진출을 본격화한 가운데 비만치료제 MariTide 2상 위장관 부작용 이슈로 주가가 하락했다. 허혜민 키움증권 연구원은 ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...